Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CCNE1 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
CCNE1 overexpression	Breast Cancer	CCNE1 overexpression	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
CCNE1 overexpression	Ovarian Cancer	CCNE1 overexpression	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CCNE1 overexpression	Endometrial Cancer	CCNE1 overexpression	Endometrial Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
CCNE1 overexpression	Ovarian Cancer	CCNE1 overexpression	Ovarian Cancer	ZN-c3 Sensitive: C3 – Early Trials ZN-c3 Sensitive : C3	ZN-c3 Sensitive: C3 – Early Trials ZN-c3 Sensitive : C3
CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	CCNE1 overexpression	Estrogen Receptor Positive Breast Cancer	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D	RGT-419B Sensitive: D – Preclinical RGT-419B Sensitive : D
CCNE1 overexpression	Ovarian Cancer	CCNE1 overexpression	Ovarian Cancer	SNS-032 Sensitive: D – Preclinical SNS-032 Sensitive : D	SNS-032 Sensitive: D – Preclinical SNS-032 Sensitive : D
CCNE1 overexpression	Triple Negative Breast Cancer	CCNE1 overexpression	Triple Negative Breast Cancer	niraparib + AZD1775 Sensitive: D – Preclinical niraparib + AZD1775 Sensitive : D	niraparib + AZD1775 Sensitive: D – Preclinical niraparib + AZD1775 Sensitive : D